alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['H1094Y'],"[{'ncitCode': 'C162676', 'drugName': 'Elzovantinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 876, 'code': '', 'color': 'Gainsboro', 'name': '', 'mainType': {'id': None, 'name': 'Non-Small Cell Lung Cancer', 'tumorForm': 'SOLID'}, 'tissue': 'Lung', 'children': {}, 'parent': None, 'level': 0, 'tumorForm': 'SOLID'}",[],['38564707'],[],"Elzovantinib is an orally available, small molecule MET tyrosine kinase inhibitor. There are promising clinical data in patients with MET H1094Y mutant non-small cell lung cancer (NSCLC) treated with elzovantinib. In case reports from the Phase I/II (NCT03993873) trial of elzovantinib in MET-altered solid tumors, a patient with MET H1094Y-mutated NSCLC treated with elzovantinib achieved a partial response (PMID: 38564707). Preclinical studies with Ba/F3 cells expressing MET H1094Y demonstrate sensitivity to elzovantinib as measured by reduced MET phosphorylation following treatment and decreased IC50 values compared to wildtype (PMID: 38564707)."
